

75

JOB-CREATING FOREIGN INVESTMENT PROJECTS IN THE HEALTHCARE SECTOR IN 2018

(BUSINESS FRANCE)



4th

LARGEST EXPORTER IN THE WORLD OF VACCINES

(GLOBAL TRADE ATLAS/IHS MARKIT)



FRANCE, the world's **5th** largest market



and the **2nd** largest in Europe for medicinal products for human use

(LEEM PHARMACEUTICAL INDUSTRY ASSOCIATION)




#1

OECD COUNTRY FOR ACCESS TO HEALTHCARE

(OECD)

KEY INFO IN
10
POINTS

MEDICINAL PRODUCTS



HEALTHCARE

MAY 2019

BUSINESS FRANCE

77, boulevard Saint-Jacques
75680 Paris Cedex 14
Tel.: +33 1 40 73 30 00



1 THE WORLD'S 5TH LARGEST MARKET

France is the fifth largest market in the world for human medicines, and the second largest in Europe. In 2017, revenues from pharmaceuticals amounted to €54 billion, nearly half of which were generated by exports. (LEEM Pharmaceutical Industry Association, 2018)

2 SANOFI: AN INNOVATIVE LEADER

In 2018, Sanofi invested €6.6 billion in R&D, more than any other French company, putting it among the 20 top companies in the world (PwC, The 2018 Global Innovation 1000 study). Sanofi conducted a total of 84 R&D projects, including 32 new molecular entities in clinical development (Sanofi, April 2019).

3 EXPORTS ON THE RISE

In 2018, French medicinal product exports increased by more than 2% to €27 billion. The European Union received 50% of all exports, while France's three main clients were the United States (€3.8 billion), Belgium (€2.4 billion) and Germany (€2.3 billion). (French Customs Authorities)

4 AN EXPORT-ORIENTED SECTOR

France's global market share in pharmaceutical exports was 5.5% in 2018 (GTA/IHS), while France's trade balance in the sector generated a surplus of more than €7 billion. Pharmaceutical products accounted for 5.6% of French exports in 2018. (French Customs Authorities)

5 EARLY ACCESS TO INNOVATIVE TREATMENTS

France took part in 12% of industrial clinical trials in the world, and nearly one in five for oncology (LEEM Pharmaceutical Industry Association, 2018). The temporary utilization authorization (TUA), almost unique in Europe, enables access to medical innovations before their marketing authorization for patients suffering from serious illnesses for which no other therapeutic alternative exists.

6 A SECTOR CREATING SKILLED JOBS

Nearly 100,000 people were employed by pharmaceutical companies in France in 2016, including more than 44,000 in manufacturing operations (LEEM Pharmaceutical Industry Association, 2018). Half of the 18,000 people working in R&D hold a research position. (French National Institute for Statistics and Economic Studies, INSEE)

7 INVESTING IN RESEARCH

The pharmaceutical industry has one of the highest business enterprise R&D budgets of any sector in France, accounting for nearly 10% of pharma company revenues (LEEM Pharmaceutical Industry Association, 2018). Business enterprise R&D expenditure of the pharmaceutical industry amounted to 13% of that for all manufacturing industries in 2017. (Ministry for Higher Education, Research and Innovation, 2019)

8 AN ATTRACTIVE SECTOR

Between 2014 and 2018, Business France recorded 160 job-creating foreign investment projects in the pharmaceuticals and biotechnologies sector in France. In 2018, the German business Merck KGaA announced it would be expanding its development center for making biological origin medicinal products in Martillac (Nouvelle Aquitaine), while South African firm Aspen expanded its production plant of injectable sterile products in Normandie.

9 WIDE RANGE OF PRODUCTS

In 2017, 955 marketing authorizations were issued in France, more than 8,000 patients were included in the temporary utilization authorization cohort, and more than 15,000 in the nominative TUA. 727 clinical trials were authorized for medicinal products. (National Agency for the Safety of Medicine and Health Products, 2018)

10 FRANCE'S PROWESS IN VACCINES

France is the world's fourth largest exporter of vaccines (GTA/IHS), with world-renowned institutions such as the Institut Pasteur International Network (RIIP), totaling 23,000 personnel overseeing 768 projects at 32 establishments in 25 countries on every continent. The RIIP plays a major role in particular against emerging infections wherever they occur across the globe.